<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01786473</url>
  </required_header>
  <id_info>
    <org_study_id>01BHR11</org_study_id>
    <nct_id>NCT01786473</nct_id>
  </id_info>
  <brief_title>Testogel® (Testosterone Gel 50mg/5g) in the Treatment of Male Hypogonadism</brief_title>
  <official_title>A Multi-center, Double Blind, Randomized, Placebo Controlled Study of Testogel® (Testosterone Gel 50mg/5g) in the Treatment of Male Hypogonadism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoires Besins International</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratoires Besins International</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of Testogel® 50mg/5g gel
      administered once daily (QD, morning dosing) compared to placebo administered once daily (QD,
      morning dosing), for 3 months, in hypogonadal men with testosterone deficiency being
      confirmed by clinical features and biochemical tests. For men with hypogonadism, treatment
      aims to restore testosterone levels to normal physiological range.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2012</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with morning serum Total Testosterone concentration within the physiological range (300 - 1000 ng/dL or 10.4 - 34.7 nmol/L) after 3 months of Testogel treatment compared to placebo-treatment</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>morning serum Total Testosterone (TT) concentration compared to placebo treatment</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>morning serum Total Testosterone (TT) concentration compared to baseline values</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum concentrations of TT, calculated free testosterone (cFT), DHT, E2, LH, and FSH, SHBG</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prostate assessments (PSA, urine flow rate, DRE, ultrasound B)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>skin integrity</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Hypogonadism</condition>
  <arm_group>
    <arm_group_label>Testogel 1% 5g QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo gel 5g QD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testogel 1%</intervention_name>
    <arm_group_label>Testogel 1% 5g QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo gel 5g QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male ages 18-68 years diagnosed as having testosterone deficiency with clinical
             symptoms

          -  A morning (8:00-10:00) serum Total Testosterone concentration of ≤ 300 ng/dL,
             confirmed by a second measurement of morning serum Total Testosterone concentration ≤
             300 ng/dL (samples to be taken 1 - 3 weeks apart)

        Exclusion Criteria:

          -  Abnormal prostate as evidenced by prostatic symptoms, prostatic masses or induration
             on rectal examination, or elevated levels of prostate specific antigen (PSA ＞ 4ng/ml)
             or a maximum urine flow rate of less than 12 ml/sec(of a urine volume greater than
             150ml) (and/or an International Prostate Symptom Score IPSS score &gt;19)

          -  Hematocrit &gt; 50%

          -  Major psychiatric illness

          -  Unable to understand the protocol or to give informed consent

          -  Use of paroxetine and clomipramine

          -  Active alcoholism

          -  History of drug abuse within the past five years;

          -  Use of drugs that might interfere with the results of the study (e.g., antiandrogen,
             estrogens or P 450 enzyme inducers, barbiturates);

          -  BMI &lt; 18 or &gt; 30 according to Chinese BMI references;

          -  Generalized skin disease that may affect absorption of T (e.g., psoriasis) or a known
             skin intolerance to alcohol;

          -  Prolactin &gt; 40 mcg/L;

          -  Untreated severe obstructive sleep apnea;.

          -  Uncontrolled or poorly controlled heart failure
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>68 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jie Jin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University First Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ellen Dhoore</last_name>
    <email>edhoore@besins-healthcare.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Peking</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2013</study_first_submitted>
  <study_first_submitted_qc>February 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2013</study_first_posted>
  <last_update_submitted>February 6, 2013</last_update_submitted>
  <last_update_submitted_qc>February 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

